Mike Flanagan
Chief Scientific & Technology Officer Avidity Biosciences, Inc.
Seminars
Wednesday 5th November 2025
Spotlighting Emerging Clinical Profiles of AOCs for Precision Therapy Applications in Muscle & Cardiac Diseases
2:30 pm
- Understanding AOCs novel therapeutic approach for targeted oligonucleotide delivery to skeletal and cardiac tissues
- Showcasing early clinical promise of AOCs in treating rare muscle diseases like DM1, FSHD, and DMD
- Explaining AOC platform extension to precision cardiology, expanding the potential of oligonucleotide-based therapies
